But it cannot be ignored that there exists weaker responses to anti-PD-L1/PD-1 immunotherapies in ovarian cancer and breast cancer [14], compared with those observed in other cancers [15–17], suggesting that an alternate strategy may be required to achieve wide-ranging responses. This evidence concerns the gene CD274 and cancer.